Lake Street raised the firm's price target on Koru Medical to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission for the oncology indication prior to year-end is "a meaningful catalyst, expects 2026 to be another year of growth acceleration and improving leverage, supporting revenue upside and multiple expansion, the analyst tells investors.
